“This investment is further evidence of our progress towards a smoke-free future. We are encouraged by the 1.4 million smokers who have already switched to IQOS around the world, and we expect this momentum to continue. This facility will help enable us to meet growing demand from adult smokers,” stated Frederic de Wilde, PMI’s Regional President for the European Union. He added, “Our ambition is that one day potentially less harmful, smoke-free products replace cigarettes to the benefit of smokers, public health, and society at large.”
The Papastratos plant in Aspropyrgos (Greece) will be PMI’s third facility fully dedicated to the manufacture of smoke-free products. In October 2016, PMI announced completion of its first facility for tobacco sticks manufacturing in Crespellano (Bologna, Italy) in addition to a pre-existing small scale Industrial Development Center in Neuchatel (Switzerland).
IQOS is one of four smoke-free product types from PMI to address adult smoker demand for potentially less harmful alternatives to cigarettes. It is a heated tobacco product launched in late 2014 in two city test markets and is expected to be available in key cities in over 30 markets in 2017. Since 2008, PMI has hired more than 400 scientists and experts and invested over USD 3 billion in research, product development, and scientific substantiation. Results of scientific research to assess the reduced-risk potential of IQOS are very promising, and the company openly shares its scientific methodologies and findings for independent third-party review and verification.
Philip Morris International Inc.
Philip Morris International Inc. (PMI) is the world’s leading international tobacco company, with six of the world's top 15 international brands and products sold in more than 180 markets. In addition to the manufacture and sale of cigarettes, including Marlboro, the number one global cigarette brand, and other tobacco products, PMI is engaged in the development and commercialization of Reduced-Risk Products (RRPs). RRPs is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and industry-leading scientific substantiation, PMI aims to provide an RRP portfolio that meets a broad spectrum of adult smoker preferences and rigorous regulatory requirements. For more information, see www.pmi.com and www.pmiscience.com
